<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411567</url>
  </required_header>
  <id_info>
    <org_study_id>CQAE397A2202</org_study_id>
    <nct_id>NCT00411567</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma</brief_title>
  <official_title>An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate/assess the treatment of moderate to severe
      asthmatics with inhaled corticosteroid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory parameters in response to a decrease in ICS compared to no change in therapy after 2 and 4 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameter/combination of parameters most sensitive to the ICS reduction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of relative data to assess sample size calculations for subsequent studies</measure>
  </secondary_outcome>
  <enrollment>26</enrollment>
  <condition>Bronchial Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled corticosteroid therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female moderate to severe asthmatic patients, from 18-75 years of age.

          -  Moderate to severe asthma, according to the GINA guidelines, for at least one year
             with no exacerbations requiring hospitalization and/or oral steroids within the
             previous three months.

          -  No concomitant lung disease or significant medical conditions

          -  Fluticasone propionate 500mcg daily or greater, or equivalent (Mometsaone 800 mcg,
             triamcinolone 2000 mcg, Flunisolide 2000 mcg, Budesonide DPI 800 mcg, Beclomathasone
             HFA 500 mcg, Beclomethasone CFC 1000 mcg, Forced expiratory volume in 1 second (FEV1)
             at screening will be ≥ 70% of the normal predicted.

          -  Evidence of asthma, demonstrated by one of the following: Historical evidence
             confirmed by their treating physician or Demonstration of ≥ 12% reversibility of FEV1
             using a standard dose of salbutamol (up to 400 µg) within 30 minutes.

          -  Female subjects of child bearing potential must be using two forms of contraception or
             postmenopausal women must have no regular menstrual bleeding for at least 2 years
             prior to inclusion.

          -  Body Mass Index between 18 and 30. Body weight should be less than 100 kg.

        Exclusion Criteria:

          -  Smokers

          -  Concomitant medications: Except for short- and long-acting β-agonists and medication
             which may be required to treat adverse events, all other medications, other than study
             drug should be avoided from screening until all of the study completion evaluations
             have been conducted. Paracetamol is acceptable.

          -  Medical conditions: history of clinically significant drug allergy; any significant
             medical condition. For example, a history of any pulmonary disorder other than asthma.

          -  Any surgical or medical condition which might significantly alter the distribution,
             metabolism or excretion of the drug.

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulation.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing or longer
             if required by local regulation.

          -  Significant illness within the two weeks prior to dosing.

          -  A past personal or close family medical history of clinically significant cardiac
             abnormalities

          -  History of history of fainting, orthostatic hypotension, sinus arrhythmia, etc.

          -  A known hypersensitivity to Fluticasone propionate or drugs similar to Fluticasone
             propionate.

          -  History of immunocompromise, including a positive HIV test result.

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  History of drug or alcohol abuse within the 12 months prior to dosing

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

